Zoetis' Stock Is About as Cheap as It's Ever Been. 1 Thing to Know Before You Buy.
Shares in animal pharmaceutical company Zoetis (ZTS 0.14%) have been under a cloud since the release of the company's fourth-quarter earnings report in mid-February. The Q4 numbers were fine, but the company's revenue guidance fell short of expectations.
Zoetis: Lots Of Growth Opportunities For This High-Quality Compounder
Zoetis is currently cheap from a historical perspective, presenting a potential buying opportunity. The company operates in a growing animal healthcare market, benefiting from trends like pet humanization and medicalization, ensuring long-term growth. ZTS has a strong track record of market outperformance, impressive margins, and a high ROIC, making it a high-quality company.
Zoetis (ZTS) Stock Declines While Market Improves: Some Information for Investors
Zoetis (ZTS) closed the most recent trading day at $163.03, moving -0.08% from the previous trading session.
Why Zoetis (ZTS) Dipped More Than Broader Market Today
The latest trading day saw Zoetis (ZTS) settling at $160.06, representing a -1% change from its previous close.
Zoetis: Focusing On The High Margin Segments
The recent divestiture of the MFA segment improves margins and returns on capital. Zoetis is focusing on more profitable segments like genetics and companion animals. The recently updated Librela label includes adverse effects and urges practitioners to discuss potential adverse reactions with clients.
Zoetis Inc. (ZTS) CFO Wetteny Joseph Hosts Barclays 27th Annual Global Healthcare (Transcript)
Zoetis Inc. (NYSE:ZTS ) Barclays 27th Annual Global Healthcare March 11, 2025 10:30 AM ET Company Participants Wetteny Joseph - Chief Financial Officer Conference Call Participants Balaji Prasad - Barclays Balaji Prasad Good morning, everyone. Thanks for joining us at the Barclays Healthcare Conference.
Zoetis (ZTS) Laps the Stock Market: Here's Why
Zoetis (ZTS) reachead $170.37 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.
Zoetis Inc. (ZTS) BofA Securities 2025 Animal Health Summit (Transcript)
Zoetis Inc. (NYSE:ZTS ) BofA Securities 2025 Animal Health Summit February 27, 2025 1:20 PM ET Company Participants Wetteny Joseph - CFO Conference Call Participants Michael Ryskin - Bank of America Operator Ladies and gentlemen, the program is about to begin. At this time, it is my pleasure to turn the program over to your host, Michael Ryskin.
A Once-in-a-Decade Opportunity: 1 Magnificent S&P 500 Dividend Stock Down 36% to Double Up on Right Now
It is a beautiful thing when you find a feel-good stock that offers market-beating potential. A perfect example of this combination today is animal healthcare specialist Zoetis (ZTS 1.93%).
Zoetis CEO on bird flu vaccine
Zoetis received a conditional license for its bird flu vaccine from the US Department of Agriculture to help fight the spread of the disease on poultry farms. Here's what CEO Kristin Peck had to say
Why Zoetis Stock Took Another Tumble Today
One day after unveiling quarterly results that disappointed the market and engendered a stock sell-off, Zoetis (ZTS -4.49%) shares again tumbled. As of late-session trading on Friday, they were down by 4%, in no small part due to several analyst price target cuts.
US grants conditional clearance to Zoetis' bird flu vaccine for poultry
Zoetis said on Friday its bird flu vaccine has received the U.S. Department of Agriculture's conditional license for use in poultry.
